Arbuckle Stuart A 4

What Happened

• Stuart A. Arbuckle, a director of Praxis Precision Medicines (PRAX), was awarded equity on June 10, 2026: 1,371 restricted stock units (RSUs) and 648 additional share-based awards reported as derivative grants. Both awards were granted at $0.00 (no cash paid) and are compensation awards rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-12 (appears timely, within the typical 2-business-day window).
• Consideration/price: $0.00 for both awards (standard for compensation grants).
• Shares owned after transaction: not specified in the filing.
• Footnote highlights:
  • F1: The 1,371 RSUs each convert to one share and vest in a single installment on the earlier of June 10, 2027 or the 2027 annual meeting; settlement will be in shares.
  • F2: The 648 awards vest in 12 equal monthly installments beginning July 10, 2026, with the final installment on the earlier of June 10, 2027 or the 2027 annual meeting.
• Transaction code: "A" (award/grant) — these are compensation awards, not purchases/sales.

Context

• These awards are standard director compensation and do not represent an open-market purchase (which some investors view as a stronger bullish signal) nor an immediate sale. The derivative/vesting schedule means value is realized only as awards vest and are settled in shares.